[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftApx-mbteoqvpLP4OxKb88HJK1jewybxrB5gXsZmxlk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":78,"rows":85},"Chinese Academy of Medical Sciences, Fuwai Hospital",[4],143,false,45,4,1306125,13,97,[14,16,19,21,24,26,29,31],{"name":15,"count":11},"Coronary Artery Disease",{"name":17,"count":18},"Hypertension",8,{"name":20,"count":18},"COPD",{"name":22,"count":23},"Coronary Heart Disease",6,{"name":25,"count":23},"Heart Failure",{"name":27,"count":28},"Hyperaldosteronism",5,{"name":30,"count":9},"Migraine",{"name":32,"count":9},"Atrial Fibrillation",[34,39,44,49,53,58,63,68,73],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06717945","The Efficacy and Safety of Remimazolam Besylate for Cardiac Anesthesia","2025-05","remimazolam besylate",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07328230","Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism","2025-12-31","Spironolactone",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05564780","Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension","2026-12-31","RASI and\u002For a single pill combination based RASI",{"nctId":50,"briefTitle":51,"date":47,"intervention":52},"NCT05598112","Effect of Gut Microbiome Intervention on Aging Via Oral FMT","FMT",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT07462325","Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease","2027-03-31","colchicine",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07511309","FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis","2027-05-31","Randomized to optimal medical therapy",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06901466","STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","2027-10-31","Experimental: Rivaroxaban monotherapy",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07007143","STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant","2028-09-30","Experimental: Aspirin monotherapy",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05462262","Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population","2029-06","Intensive lipid-lowering control",[79,80,81,82,83,84],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[86,126,150,168,190,208,252,275,293,314,334,358,376,401,451,487,524,550,578,596,623,641,659,677,702,720,747,777,804,831,849,867,891,973,1006,1043,1073,1103,1121,1139,1157,1175,1200,1226,1244,1270,1295,1313,1336,1354,1379],{"intervention":57,"totalTrials":87,"cells":88},2,{"EARLY_PHASE1":89,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":124},{"trials":90,"activeCount":91},[],0,{"trials":93,"activeCount":91},[],{"trials":95,"activeCount":91},[],{"trials":97,"activeCount":91},[],{"trials":99,"activeCount":123,"soonestReadout":56},[100,108],{"nctId":54,"briefTitle":55,"status":101,"phases":102,"primaryCompletion":56,"completion":56,"start":103,"enrollment":104,"conditions":105,"interventions":107},"NOT_YET_RECRUITING",[83],"2026-03-01",176,[106],"Coronary Heart Disease (CHD)",[57],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":122},"NCT06025071","Residual Inflammatory Risk-Guided colcHicine in Elderly Trial","UNKNOWN",[83],"2025-09","2025-10","2023-09",800,[118,119,120,121],"Percutaneous Coronary Intervention","Multivessel Coronary Artery Disease","Elderly Patients","C-Reactive Protein",[57],1,{"trials":125,"activeCount":91},[],{"intervention":72,"totalTrials":123,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":148},{"trials":129,"activeCount":91},[],{"trials":131,"activeCount":91},[],{"trials":133,"activeCount":91},[],{"trials":135,"activeCount":91},[],{"trials":137,"activeCount":123,"soonestReadout":71},[138],{"nctId":69,"briefTitle":70,"status":139,"phases":140,"primaryCompletion":71,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},"RECRUITING",[83],"2029-09-30","2025-07-31",1032,[145],"Mitral Regurgitation",[72,147],"Active Comparator: Aspirin+Clopidogrel",{"trials":149,"activeCount":91},[],{"intervention":147,"totalTrials":123,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":166},{"trials":153,"activeCount":91},[],{"trials":155,"activeCount":91},[],{"trials":157,"activeCount":91},[],{"trials":159,"activeCount":91},[],{"trials":161,"activeCount":123,"soonestReadout":71},[162],{"nctId":69,"briefTitle":70,"status":139,"phases":163,"primaryCompletion":71,"completion":141,"start":142,"enrollment":143,"conditions":164,"interventions":165},[83],[145],[72,147],{"trials":167,"activeCount":91},[],{"intervention":67,"totalTrials":123,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":188},{"trials":171,"activeCount":91},[],{"trials":173,"activeCount":91},[],{"trials":175,"activeCount":91},[],{"trials":177,"activeCount":91},[],{"trials":179,"activeCount":123,"soonestReadout":66},[180],{"nctId":64,"briefTitle":65,"status":139,"phases":181,"primaryCompletion":66,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},[83],"2028-10-31","2025-06-13",880,[145],[67,187],"Active Comparator: Rivaroxaban+Clopidogrel",{"trials":189,"activeCount":91},[],{"intervention":187,"totalTrials":123,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":206},{"trials":193,"activeCount":91},[],{"trials":195,"activeCount":91},[],{"trials":197,"activeCount":91},[],{"trials":199,"activeCount":91},[],{"trials":201,"activeCount":123,"soonestReadout":66},[202],{"nctId":64,"briefTitle":65,"status":139,"phases":203,"primaryCompletion":66,"completion":182,"start":183,"enrollment":184,"conditions":204,"interventions":205},[83],[145],[67,187],{"trials":207,"activeCount":91},[],{"intervention":52,"totalTrials":209,"cells":210},3,{"EARLY_PHASE1":211,"PHASE1":232,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":250},{"trials":212,"activeCount":123,"soonestReadout":47},[213,222],{"nctId":50,"briefTitle":51,"status":139,"phases":214,"primaryCompletion":47,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":221},[79],"2027-12-31","2023-04-24",210,[219,220],"Aging","Frailty",[52],{"nctId":223,"briefTitle":224,"status":111,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":231},"NCT04406129","Effect of Gut Microbiome Restoration on Primary Hypertension Via FMT",[79],"2022-02-01","2022-09-01","2021-03-17",120,[17],[52],{"trials":233,"activeCount":91},[234],{"nctId":235,"briefTitle":236,"status":111,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT05608447","Effect of Intensive FMT on Primary Hypertension",[80],"2023-06-01","2023-09-30","2023-01-01",72,[17],[52],{"trials":245,"activeCount":91},[],{"trials":247,"activeCount":91},[],{"trials":249,"activeCount":91},[],{"trials":251,"activeCount":91},[],{"intervention":38,"totalTrials":123,"cells":253},{"EARLY_PHASE1":254,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":273},{"trials":255,"activeCount":123,"soonestReadout":37},[256],{"nctId":35,"briefTitle":36,"status":101,"phases":257,"primaryCompletion":37,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},[79],"2025-06","2025-01",320,[262],"Anesthesia",[38,264],"propofol",{"trials":266,"activeCount":91},[],{"trials":268,"activeCount":91},[],{"trials":270,"activeCount":91},[],{"trials":272,"activeCount":91},[],{"trials":274,"activeCount":91},[],{"intervention":264,"totalTrials":123,"cells":276},{"EARLY_PHASE1":277,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":278,"activeCount":123,"soonestReadout":37},[279],{"nctId":35,"briefTitle":36,"status":101,"phases":280,"primaryCompletion":37,"completion":258,"start":259,"enrollment":260,"conditions":281,"interventions":282},[79],[262],[38,264],{"trials":284,"activeCount":91},[],{"trials":286,"activeCount":91},[],{"trials":288,"activeCount":91},[],{"trials":290,"activeCount":91},[],{"trials":292,"activeCount":91},[],{"intervention":43,"totalTrials":123,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":305},{"trials":296,"activeCount":91},[],{"trials":298,"activeCount":91},[],{"trials":300,"activeCount":91},[],{"trials":302,"activeCount":91},[],{"trials":304,"activeCount":91},[],{"trials":306,"activeCount":123,"soonestReadout":42},[307],{"nctId":40,"briefTitle":41,"status":139,"phases":308,"primaryCompletion":42,"completion":42,"start":309,"enrollment":310,"conditions":311,"interventions":313},[84],"2022-08-01",172,[312,27],"Idiopathic Hyperaldosteronism",[43],{"intervention":48,"totalTrials":123,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":326},{"trials":317,"activeCount":91},[],{"trials":319,"activeCount":91},[],{"trials":321,"activeCount":91},[],{"trials":323,"activeCount":91},[],{"trials":325,"activeCount":91},[],{"trials":327,"activeCount":123,"soonestReadout":47},[328],{"nctId":45,"briefTitle":46,"status":101,"phases":329,"primaryCompletion":47,"completion":47,"start":240,"enrollment":330,"conditions":331,"interventions":333},[84],20000,[332],"Cardiovascular Diseases",[48],{"intervention":77,"totalTrials":123,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":337,"activeCount":91},[],{"trials":339,"activeCount":91},[],{"trials":341,"activeCount":91},[],{"trials":343,"activeCount":91},[],{"trials":345,"activeCount":91},[],{"trials":347,"activeCount":123,"soonestReadout":76},[348],{"nctId":74,"briefTitle":75,"status":349,"phases":350,"primaryCompletion":76,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"ENROLLING_BY_INVITATION",[84],"2029-10","2022-10-10",2900,[355],"Coronary Artery Disease Progression",[77,357],"Moderate-intensity lipid-lowering control",{"intervention":357,"totalTrials":123,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":370},{"trials":361,"activeCount":91},[],{"trials":363,"activeCount":91},[],{"trials":365,"activeCount":91},[],{"trials":367,"activeCount":91},[],{"trials":369,"activeCount":91},[],{"trials":371,"activeCount":123,"soonestReadout":76},[372],{"nctId":74,"briefTitle":75,"status":349,"phases":373,"primaryCompletion":76,"completion":351,"start":352,"enrollment":353,"conditions":374,"interventions":375},[84],[355],[77,357],{"intervention":62,"totalTrials":123,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":379,"activeCount":91},[],{"trials":381,"activeCount":91},[],{"trials":383,"activeCount":91},[],{"trials":385,"activeCount":91},[],{"trials":387,"activeCount":91},[],{"trials":389,"activeCount":123,"soonestReadout":61},[390],{"nctId":59,"briefTitle":60,"status":101,"phases":391,"primaryCompletion":61,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":400},[84],"2028-03-31","2026-03-31",300,[396,397,398,399],"Atherosclerotic Renal Artery Stenosis","Fractional Flow Reserve","Optimal Medical Therapy","Stent Implantation",[62],{"intervention":402,"totalTrials":209,"cells":403},"Atorvastatin",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":422,"PHASE4":424,"NA":449},{"trials":405,"activeCount":91},[],{"trials":407,"activeCount":91},[],{"trials":409,"activeCount":91},[410],{"nctId":411,"briefTitle":412,"status":413,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":421},"NCT00615823","Atorvastatin in Pulmonary Hypertension","COMPLETED",[81],"2010-03","2010-05","2007-02",220,[420],"Hypertension, Pulmonary",[402],{"trials":423,"activeCount":91},[],{"trials":425,"activeCount":91},[426,436],{"nctId":427,"briefTitle":428,"status":111,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":394,"conditions":433,"interventions":434},"NCT02254824","Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients",[83],"2015-10","2016-10","2013-10",[17],[435,402],"Xuezhikang",{"nctId":437,"briefTitle":438,"status":111,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":447},"NCT04945122","Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in AMI Patients With Abnormal Glucose Metabolism",[83],"2022-12-31","2023-12-31","2015-10-01",900,[445,446],"Acute Myocardial Infarction","Glucose Metabolism Disorders",[448,402],"Pitavastatin",{"trials":450,"activeCount":91},[],{"intervention":452,"totalTrials":87,"cells":453},"Aspirin",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":472,"NA":485},{"trials":455,"activeCount":91},[],{"trials":457,"activeCount":91},[],{"trials":459,"activeCount":91},[],{"trials":461,"activeCount":91},[462],{"nctId":463,"briefTitle":464,"status":111,"phases":465,"primaryCompletion":466,"start":415,"enrollment":467,"conditions":468,"interventions":470},"NCT01268917","The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass",[82],"2011-03",200,[15,469,452],"Off-pump Coronary Artery Bypass",[471,471],"aspirin",{"trials":473,"activeCount":91},[474],{"nctId":475,"briefTitle":476,"status":111,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT05561660","COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2)",[83],"2024-10-01","2025-10-01","2022-10-01",460,[30,483],"Patent Foramen Ovale",[452],{"trials":486,"activeCount":91},[],{"intervention":488,"totalTrials":87,"cells":489},"Levothyroxine",{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":522},{"trials":491,"activeCount":91},[],{"trials":493,"activeCount":91},[],{"trials":495,"activeCount":91},[],{"trials":497,"activeCount":91},[],{"trials":499,"activeCount":91},[500,510],{"nctId":501,"briefTitle":502,"status":111,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT03096613","Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)",[83],"2019-02","2017-04-18",124,[25,508],"Subclinical Hypothyroidism",[488],{"nctId":511,"briefTitle":512,"status":111,"phases":513,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":521},"NCT02512978","Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)",[83],"2018-12","2019-06","2015-08",160,[519,520],"Myocardial Infarction","Hypothyroidism",[488],{"trials":523,"activeCount":91},[],{"intervention":525,"totalTrials":123,"cells":526},"Amlodipine, Telmisartan, Amiloride Compound , Simvastatin",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":548},{"trials":528,"activeCount":91},[],{"trials":530,"activeCount":91},[],{"trials":532,"activeCount":91},[],{"trials":534,"activeCount":91},[],{"trials":536,"activeCount":91},[537],{"nctId":538,"briefTitle":539,"status":111,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":547},"NCT01011660","Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients",[83],"2012-08","2012-12","2007-10",13542,[546],"Essential Hypertension",[525],{"trials":549,"activeCount":91},[],{"intervention":551,"totalTrials":123,"cells":552},"Tranexamic Acid Dosage 1",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":561,"NA":576},{"trials":554,"activeCount":91},[],{"trials":556,"activeCount":91},[],{"trials":558,"activeCount":91},[],{"trials":560,"activeCount":91},[],{"trials":562,"activeCount":91},[563],{"nctId":564,"briefTitle":565,"status":413,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":574},"NCT03782350","Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass",[83],"2021-09-30","2021-11-27","2018-12-26",3079,[572,573],"Homeostasis","Cardiac Surgery",[551,575],"Tranexamic Acid Dosage 2",{"trials":577,"activeCount":91},[],{"intervention":575,"totalTrials":123,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":594},{"trials":581,"activeCount":91},[],{"trials":583,"activeCount":91},[],{"trials":585,"activeCount":91},[],{"trials":587,"activeCount":91},[],{"trials":589,"activeCount":91},[590],{"nctId":564,"briefTitle":565,"status":413,"phases":591,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":592,"interventions":593},[83],[572,573],[551,575],{"trials":595,"activeCount":91},[],{"intervention":597,"totalTrials":123,"cells":598},"ticagrelor",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":607,"NA":621},{"trials":600,"activeCount":91},[],{"trials":602,"activeCount":91},[],{"trials":604,"activeCount":91},[],{"trials":606,"activeCount":91},[],{"trials":608,"activeCount":91},[609],{"nctId":610,"briefTitle":611,"status":413,"phases":612,"primaryCompletion":431,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT02330640","A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting",[83],"2016-10-01","2016-01",137,[617],"Antiplatelet Therapy of Coronary Artery Bypass",[597,619,620],"clopidogrel","asprin",{"trials":622,"activeCount":91},[],{"intervention":619,"totalTrials":123,"cells":624},{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":633,"NA":639},{"trials":626,"activeCount":91},[],{"trials":628,"activeCount":91},[],{"trials":630,"activeCount":91},[],{"trials":632,"activeCount":91},[],{"trials":634,"activeCount":91},[635],{"nctId":610,"briefTitle":611,"status":413,"phases":636,"primaryCompletion":431,"completion":613,"start":614,"enrollment":615,"conditions":637,"interventions":638},[83],[617],[597,619,620],{"trials":640,"activeCount":91},[],{"intervention":620,"totalTrials":123,"cells":642},{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":657},{"trials":644,"activeCount":91},[],{"trials":646,"activeCount":91},[],{"trials":648,"activeCount":91},[],{"trials":650,"activeCount":91},[],{"trials":652,"activeCount":91},[653],{"nctId":610,"briefTitle":611,"status":413,"phases":654,"primaryCompletion":431,"completion":613,"start":614,"enrollment":615,"conditions":655,"interventions":656},[83],[617],[597,619,620],{"trials":658,"activeCount":91},[],{"intervention":435,"totalTrials":123,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":675},{"trials":662,"activeCount":91},[],{"trials":664,"activeCount":91},[],{"trials":666,"activeCount":91},[],{"trials":668,"activeCount":91},[],{"trials":670,"activeCount":91},[671],{"nctId":427,"briefTitle":428,"status":111,"phases":672,"primaryCompletion":430,"completion":431,"start":432,"enrollment":394,"conditions":673,"interventions":674},[83],[17],[435,402],{"trials":676,"activeCount":91},[],{"intervention":678,"totalTrials":123,"cells":679},"Qishenyiqi dropping pills",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":700},{"trials":681,"activeCount":91},[],{"trials":683,"activeCount":91},[],{"trials":685,"activeCount":91},[],{"trials":687,"activeCount":91},[],{"trials":689,"activeCount":91},[690],{"nctId":691,"briefTitle":692,"status":111,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT04028544","The Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients",[83],"2020-09","2021-09","2019-03-26",5380,[25],[678],{"trials":701,"activeCount":91},[],{"intervention":448,"totalTrials":123,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":718},{"trials":705,"activeCount":91},[],{"trials":707,"activeCount":91},[],{"trials":709,"activeCount":91},[],{"trials":711,"activeCount":91},[],{"trials":713,"activeCount":91},[714],{"nctId":437,"briefTitle":438,"status":111,"phases":715,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":716,"interventions":717},[83],[445,446],[448,402],{"trials":719,"activeCount":91},[],{"intervention":721,"totalTrials":123,"cells":722},"Prednisone, cyclophosphamide",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":743,"NA":745},{"trials":724,"activeCount":91},[],{"trials":726,"activeCount":91},[],{"trials":728,"activeCount":91},[],{"trials":730,"activeCount":91},[731],{"nctId":732,"briefTitle":733,"status":111,"phases":734,"primaryCompletion":735,"completion":736,"start":737,"enrollment":738,"conditions":739,"interventions":742},"NCT03550781","Anti-inflammatory Treatment for Inactive Takayasu Arteritis",[81,82],"2020-05-31","2021-05-31","2018-06-01",40,[740,741],"Takayasu Arteritis","Anti-Inflammatory Agents",[721],{"trials":744,"activeCount":91},[],{"trials":746,"activeCount":91},[],{"intervention":748,"totalTrials":123,"cells":749},"Rosuvastatin",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":773,"NA":775},{"trials":751,"activeCount":91},[],{"trials":753,"activeCount":91},[],{"trials":755,"activeCount":91},[],{"trials":757,"activeCount":91},[758],{"nctId":759,"briefTitle":760,"status":413,"phases":761,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":772},"NCT03521700","Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement",[81,82],"2014-12-30","2015-12-30","2013-06-01",150,[767,768,769,770,771],"Renal Artery Obstruction","Stents","Lipids","Glomerular Filtration Rate","Blood Pressure",[748],{"trials":774,"activeCount":91},[],{"trials":776,"activeCount":91},[],{"intervention":778,"totalTrials":123,"cells":779},"Atorvastatin and mononuclear cells transplantation",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":781,"activeCount":91},[],{"trials":783,"activeCount":91},[],{"trials":785,"activeCount":91},[786],{"nctId":787,"briefTitle":788,"status":413,"phases":789,"primaryCompletion":790,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":797},"NCT00979758","Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction",[81],"2015-06","2016-06","2009-01",100,[519,795,796],"Stem Cell Transplantation","Angioplasty, Transluminal, Percutaneous Coronary",[778],{"trials":799,"activeCount":91},[],{"trials":801,"activeCount":91},[],{"trials":803,"activeCount":91},[],{"intervention":805,"totalTrials":123,"cells":806},"Aspirin 300mg",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":808,"activeCount":91},[],{"trials":810,"activeCount":91},[],{"trials":812,"activeCount":91},[813],{"nctId":814,"briefTitle":815,"status":413,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":821},"NCT05546320","Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale",[81],"2025-03-26","2022-10-15",1000,[483,30],[805,822,823,824],"Metoprolol 25mg","Clopidogrel 75mg","Rivaroxaban 20mg",{"trials":826,"activeCount":91},[],{"trials":828,"activeCount":91},[],{"trials":830,"activeCount":91},[],{"intervention":822,"totalTrials":123,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":834,"activeCount":91},[],{"trials":836,"activeCount":91},[],{"trials":838,"activeCount":91},[839],{"nctId":814,"briefTitle":815,"status":413,"phases":840,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":841,"interventions":842},[81],[483,30],[805,822,823,824],{"trials":844,"activeCount":91},[],{"trials":846,"activeCount":91},[],{"trials":848,"activeCount":91},[],{"intervention":824,"totalTrials":123,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":852,"activeCount":91},[],{"trials":854,"activeCount":91},[],{"trials":856,"activeCount":91},[857],{"nctId":814,"briefTitle":815,"status":413,"phases":858,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":859,"interventions":860},[81],[483,30],[805,822,823,824],{"trials":862,"activeCount":91},[],{"trials":864,"activeCount":91},[],{"trials":866,"activeCount":91},[],{"intervention":868,"totalTrials":123,"cells":869},"Probiotic powder",{"EARLY_PHASE1":870,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":871,"activeCount":91},[872],{"nctId":873,"briefTitle":874,"status":413,"phases":875,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":879,"interventions":880},"NCT05095350","Effect of Probiotics on Primary Hypertension",[79],"2023-06-02","2021-12-05",115,[17],[868],{"trials":882,"activeCount":91},[],{"trials":884,"activeCount":91},[],{"trials":886,"activeCount":91},[],{"trials":888,"activeCount":91},[],{"trials":890,"activeCount":91},[],{"intervention":892,"totalTrials":23,"cells":893},"Tranexamic Acid",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":916},{"trials":895,"activeCount":91},[],{"trials":897,"activeCount":91},[],{"trials":899,"activeCount":91},[],{"trials":901,"activeCount":91},[],{"trials":903,"activeCount":91},[904],{"nctId":905,"briefTitle":906,"status":413,"phases":907,"primaryCompletion":908,"completion":909,"start":910,"enrollment":217,"conditions":911,"interventions":914},"NCT04911413","Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery",[83],"2021-03-05","2021-06-15","2017-09-01",[912,913,892],"Cardiac Surgical Procedures","Blood Transfusion",[915],"Tranexamic acid",{"trials":917,"activeCount":91},[918,930,941,951,963],{"nctId":919,"briefTitle":920,"status":413,"phases":921,"primaryCompletion":792,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT01060189","Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery",[84],"2019-01","2008-04",426,[926],"Hemostasis",[928,892,929],"Ulinastatin","Saline Solution",{"nctId":931,"briefTitle":932,"status":413,"phases":933,"primaryCompletion":934,"completion":935,"start":936,"enrollment":937,"conditions":938,"interventions":940},"NCT01064167","Tranexamic Acid in Off-pump Coronary Surgery",[84],"2009-10","2009-12","2009-02",231,[939],"Off Pump Coronary Artery Bypass Surgery",[892],{"nctId":942,"briefTitle":943,"status":111,"phases":944,"primaryCompletion":945,"completion":946,"start":947,"enrollment":948,"conditions":949,"interventions":950},"NCT01060176","Three Dose Regimen of Tranexamic Acid in Cardiac Surgery",[84],"2019-08","2019-12","2010-02",600,[926],[892,929],{"nctId":952,"briefTitle":953,"status":413,"phases":954,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":962},"NCT01191554","Dose-ranging Study of Tranexamic Acid in Valve Surgery",[84],"2011-09","2011-10","2010-09",175,[960,961],"Hemorrhage","Valvular Heart Surgery",[892],{"nctId":964,"briefTitle":965,"status":413,"phases":966,"primaryCompletion":967,"completion":956,"start":968,"enrollment":969,"conditions":970,"interventions":971},"NCT01060163","Tranexamic Acid in Clopidogrel Exposure to Decrease Hemorrhage and Transfusion",[84],"2011-06","2010-01",552,[15],[892,972],"Saline",{"intervention":929,"totalTrials":209,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":976,"activeCount":91},[],{"trials":978,"activeCount":91},[],{"trials":980,"activeCount":91},[],{"trials":982,"activeCount":91},[],{"trials":984,"activeCount":91},[],{"trials":986,"activeCount":91},[987,991,995],{"nctId":919,"briefTitle":920,"status":413,"phases":988,"primaryCompletion":792,"completion":922,"start":923,"enrollment":924,"conditions":989,"interventions":990},[84],[926],[928,892,929],{"nctId":942,"briefTitle":943,"status":111,"phases":992,"primaryCompletion":945,"completion":946,"start":947,"enrollment":948,"conditions":993,"interventions":994},[84],[926],[892,929],{"nctId":996,"briefTitle":997,"status":413,"phases":998,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":793,"conditions":1002,"interventions":1004},"NCT03826004","Clemastine in Cardiovascular Surgery",[84],"2019-07-31","2020-01-10","2019-02-20",[1003],"Efficacy and Safety",[1005,929],"Clemastine",{"intervention":1007,"totalTrials":87,"cells":1008},"Warfarin",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1010,"activeCount":91},[],{"trials":1012,"activeCount":91},[],{"trials":1014,"activeCount":91},[],{"trials":1016,"activeCount":91},[],{"trials":1018,"activeCount":91},[],{"trials":1020,"activeCount":91},[1021,1032],{"nctId":1022,"briefTitle":1023,"status":111,"phases":1024,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1031},"NCT03185845","The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism",[84],"2020-12-31","2017-06-15",392,[1029,1030],"COPD Exacerbation","PTE - Pulmonary Thromboembolism",[1007],{"nctId":1033,"briefTitle":1034,"status":111,"phases":1035,"primaryCompletion":1036,"completion":1037,"start":1038,"enrollment":819,"conditions":1039,"interventions":1042},"NCT01855737","The Study of Warfarin Maintenance Dose in Chinese Patients",[],"2013-12","2014-01","2013-06",[32,1040,1041],"Heart Valve Disease","Pulmonary Artery Embolism",[1007],{"intervention":823,"totalTrials":87,"cells":1044},{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1046,"activeCount":91},[],{"trials":1048,"activeCount":91},[],{"trials":1050,"activeCount":91},[1051],{"nctId":814,"briefTitle":815,"status":413,"phases":1052,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":1053,"interventions":1054},[81],[483,30],[805,822,823,824],{"trials":1056,"activeCount":91},[],{"trials":1058,"activeCount":91},[],{"trials":1060,"activeCount":91},[1061],{"nctId":1062,"briefTitle":1063,"status":413,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1069},"NCT01779401","Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients",[84],"2016-09","2012-09",1078,[22],[823,1070,1071,1072],"Clopidogrel 150mg","Aspirin 100mg","Cilostazol 100mg",{"intervention":1074,"totalTrials":87,"cells":1075},"saline",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1077,"activeCount":91},[],{"trials":1079,"activeCount":91},[],{"trials":1081,"activeCount":91},[],{"trials":1083,"activeCount":91},[],{"trials":1085,"activeCount":91},[],{"trials":1087,"activeCount":91},[1088,1099],{"nctId":1089,"briefTitle":1090,"status":111,"phases":1091,"primaryCompletion":1092,"completion":1093,"start":1026,"enrollment":1094,"conditions":1095,"interventions":1097},"NCT03186053","Sodium Creatine Phosphate in Heart Valve Surgery",[84],"2018-07-01","2018-12-31",250,[1096],"Heart Valve Diseases",[1098,1074],"sodium creatine phosphate",{"nctId":964,"briefTitle":965,"status":413,"phases":1100,"primaryCompletion":967,"completion":956,"start":968,"enrollment":969,"conditions":1101,"interventions":1102},[84],[15],[892,972],{"intervention":1070,"totalTrials":123,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":91},[],{"trials":1108,"activeCount":91},[],{"trials":1110,"activeCount":91},[],{"trials":1112,"activeCount":91},[],{"trials":1114,"activeCount":91},[],{"trials":1116,"activeCount":91},[1117],{"nctId":1062,"briefTitle":1063,"status":413,"phases":1118,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1119,"interventions":1120},[84],[22],[823,1070,1071,1072],{"intervention":1071,"totalTrials":123,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1124,"activeCount":91},[],{"trials":1126,"activeCount":91},[],{"trials":1128,"activeCount":91},[],{"trials":1130,"activeCount":91},[],{"trials":1132,"activeCount":91},[],{"trials":1134,"activeCount":91},[1135],{"nctId":1062,"briefTitle":1063,"status":413,"phases":1136,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1137,"interventions":1138},[84],[22],[823,1070,1071,1072],{"intervention":1072,"totalTrials":123,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1142,"activeCount":91},[],{"trials":1144,"activeCount":91},[],{"trials":1146,"activeCount":91},[],{"trials":1148,"activeCount":91},[],{"trials":1150,"activeCount":91},[],{"trials":1152,"activeCount":91},[1153],{"nctId":1062,"briefTitle":1063,"status":413,"phases":1154,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1155,"interventions":1156},[84],[22],[823,1070,1071,1072],{"intervention":928,"totalTrials":123,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1160,"activeCount":91},[],{"trials":1162,"activeCount":91},[],{"trials":1164,"activeCount":91},[],{"trials":1166,"activeCount":91},[],{"trials":1168,"activeCount":91},[],{"trials":1170,"activeCount":91},[1171],{"nctId":919,"briefTitle":920,"status":413,"phases":1172,"primaryCompletion":792,"completion":922,"start":923,"enrollment":924,"conditions":1173,"interventions":1174},[84],[926],[928,892,929],{"intervention":1176,"totalTrials":123,"cells":1177},"The tetralogy of medication regimen",{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1179,"activeCount":91},[],{"trials":1181,"activeCount":91},[],{"trials":1183,"activeCount":91},[],{"trials":1185,"activeCount":91},[],{"trials":1187,"activeCount":91},[],{"trials":1189,"activeCount":91},[1190],{"nctId":1191,"briefTitle":1192,"status":413,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT06553391","Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis",[],"2025-01-01","2025-05-30","2024-08-01",106,[32],[1176],{"intervention":1201,"totalTrials":123,"cells":1202},"Intensive BP control",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1204,"activeCount":91},[],{"trials":1206,"activeCount":91},[],{"trials":1208,"activeCount":91},[],{"trials":1210,"activeCount":91},[],{"trials":1212,"activeCount":91},[],{"trials":1214,"activeCount":91},[1215],{"nctId":1216,"briefTitle":1217,"status":111,"phases":1218,"primaryCompletion":1025,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1224},"NCT03015311","Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients",[84],"2021-12-31","2017-01-15",8000,[1223],"Primary Hypertension",[1201,1225],"Standard BP control",{"intervention":1225,"totalTrials":123,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1229,"activeCount":91},[],{"trials":1231,"activeCount":91},[],{"trials":1233,"activeCount":91},[],{"trials":1235,"activeCount":91},[],{"trials":1237,"activeCount":91},[],{"trials":1239,"activeCount":91},[1240],{"nctId":1216,"briefTitle":1217,"status":111,"phases":1241,"primaryCompletion":1025,"completion":1219,"start":1220,"enrollment":1221,"conditions":1242,"interventions":1243},[84],[1223],[1201,1225],{"intervention":1245,"totalTrials":123,"cells":1246},"standard medical treatment",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1248,"activeCount":91},[],{"trials":1250,"activeCount":91},[],{"trials":1252,"activeCount":91},[],{"trials":1254,"activeCount":91},[],{"trials":1256,"activeCount":91},[],{"trials":1258,"activeCount":91},[1259],{"nctId":1260,"briefTitle":1261,"status":111,"phases":1262,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":819,"conditions":1266,"interventions":1269},"NCT03535532","Unilateral Laparoscopic Adrenalectomy for Resistant Hypertension in Patients With Adrenal Diseases",[84],"2020-10-20","2021-12-20","2018-12-20",[1267,1268],"Resistant Hypertension","Adrenal Disease",[1245],{"intervention":1271,"totalTrials":123,"cells":1272},"Naoxintong",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1274,"activeCount":91},[],{"trials":1276,"activeCount":91},[],{"trials":1278,"activeCount":91},[],{"trials":1280,"activeCount":91},[],{"trials":1282,"activeCount":91},[],{"trials":1284,"activeCount":91},[1285],{"nctId":1286,"briefTitle":1287,"status":111,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1294},"NCT05278182","A Study for Exploring the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque on the Basis of Optimal Medical Therapy (Aspirin,Statins,Clopidogrel, Etc.): Stage One",[84],"2025-06-30","2022-12",80,[1293],"Atherosclerotic Cardiovascular Disease",[1271],{"intervention":1005,"totalTrials":123,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1298,"activeCount":91},[],{"trials":1300,"activeCount":91},[],{"trials":1302,"activeCount":91},[],{"trials":1304,"activeCount":91},[],{"trials":1306,"activeCount":91},[],{"trials":1308,"activeCount":91},[1309],{"nctId":996,"briefTitle":997,"status":413,"phases":1310,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":793,"conditions":1311,"interventions":1312},[84],[1003],[1005,929],{"intervention":1314,"totalTrials":123,"cells":1315},"Sildenafil Citrate",{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1317,"activeCount":91},[],{"trials":1319,"activeCount":91},[],{"trials":1321,"activeCount":91},[],{"trials":1323,"activeCount":91},[],{"trials":1325,"activeCount":91},[],{"trials":1327,"activeCount":91},[1328],{"nctId":1329,"briefTitle":1330,"status":111,"phases":1331,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":1332,"conditions":1333,"interventions":1335},"NCT03185364","The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD",[84],46,[20,1334],"Pulmonary Hypertension",[1314],{"intervention":1098,"totalTrials":123,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1339,"activeCount":91},[],{"trials":1341,"activeCount":91},[],{"trials":1343,"activeCount":91},[],{"trials":1345,"activeCount":91},[],{"trials":1347,"activeCount":91},[],{"trials":1349,"activeCount":91},[1350],{"nctId":1089,"briefTitle":1090,"status":111,"phases":1351,"primaryCompletion":1092,"completion":1093,"start":1026,"enrollment":1094,"conditions":1352,"interventions":1353},[84],[1096],[1098,1074],{"intervention":1355,"totalTrials":123,"cells":1356},"mavacamten",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1358,"activeCount":91},[],{"trials":1360,"activeCount":91},[],{"trials":1362,"activeCount":91},[],{"trials":1364,"activeCount":91},[],{"trials":1366,"activeCount":91},[],{"trials":1368,"activeCount":91},[1369],{"nctId":1370,"briefTitle":1371,"status":413,"phases":1372,"primaryCompletion":1195,"completion":1289,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1378},"NCT07529938","Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy",[],"2024-01-01",222,[1376,1377],"Hypertrophic Cardiomyopathy (HCM)","Obstructive Hypertrophic Cardiomyopathy (oHCM)",[1355],{"intervention":1380,"totalTrials":123,"cells":1381},"Exenatide",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1383,"activeCount":91},[],{"trials":1385,"activeCount":91},[],{"trials":1387,"activeCount":91},[],{"trials":1389,"activeCount":91},[],{"trials":1391,"activeCount":91},[],{"trials":1393,"activeCount":91},[1394],{"nctId":1395,"briefTitle":1396,"status":111,"phases":1397,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1403},"NCT02344641","Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients",[84],"2016-12","2015-01",234,[1402,25],"Type 2 Diabetes Mellitus",[1380]]